Jetrea, aka ocriplasmin, manufactured by Thrombogenics is FDA approved to enzymatically induce, or create, a posterior vitreous detachment. By creating a PVD, several retinal diseases might be treated without conventional eye surgery such as vitrectomy.
I recently started using Jetrea for treatment of vitreomacular adhesion, coined VMA. This is also known as vitreomacular traction (VMT). It is not dissimilar to an epiretinal membrane where the (Read more...)